Durga Prasad Mishra

Durga Prasad Mishra

Auto-generated profile, based on publicly available information

Durga Prasad Mishra

CSIR-Central Drug Research Institute (CDRI)

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in Medicinal Research Reviews
Verified
Journal Article
Closed access
JRJyotika Rajawat
Jyotika Rajawat
NSNidhi Shukla
Nidhi Shukla
DMDurga Prasad Mishra
Durga Prasad Mishra

4 February 2026 in Journal of Proteome Research
Verified
Journal Article
Closed access
RSRashi Saxena
Rashi Saxena
VBVinod Singh Bisht
Vinod Singh Bisht
DKDeepak Kumar
Deepak Kumar
DEDeepak
Deepak
RYRekha Yadav
Rekha Yadav
DMDurga Prasad Mishra
Durga Prasad Mishra

20 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJyotika Rajawat
Jyotika Rajawat
NSNidhi Shukla
Nidhi Shukla
ASAkanchha Shukla
Akanchha Shukla
MSManohar Singh
Manohar Singh
AJAijaz Ahmad John
Aijaz Ahmad John
DMDurga Prasad Mishra
Durga Prasad Mishra
Background and Purpose: PARP inhibitors have been evaluated in clinical trials for several cancers and Olaparib is FDA approved for treating BRCA deficient ovarian cancer. Numerous reports have suggested Poly(ADP-ribose) polymerase1(PARP1) overexpression in a variety of cancers including breast carcinomas and proposed the role of PARP1 in metastasis. However, the mechanism of PARP1 in regulating metastatic process in BRCA proficient and deficient TNBC is not studied thoroughly. In this study, we propose that PARP1 mediated breast carcinoma progression is gene transcription mediated, where it regulates several steps of pro-metastasis. Experimental Approach: PARP inhibitor’s effect on metastasis was monitored by migration and invasion assay, modulation in protein expression was assessed by proteomic analysis and further confirmed by immunoblotting. Chromatin immunoprecipitation was performed to study the transcriptional role of PARP1. Ectopic expression and siRhoGDIα, and immunofluorescence assessed the cytoskeleton changes. PARP inhibitor was administered in xenograft mice to study metastasis. Immunohistochemical analysis was done on patient and mice tissues. Key results: Breast cancer cells exhibited reduced migration and invasion due to PARP1 inhibition. PARP1 regulates expression of vimentin and RhoGDIα and hence cytoskeletal rearrangement causing a change in migrating potential of a cell. Metastasis in mice was reduced upon PARP inhibition. PARP1 was identified to be a novel transcriptional regulator of RhoGDIα. Furthermore, RhoGDIα ectopic expression substantiated the PARP inhibitor effects, suggesting the PARP inhibitor downstream signaling to be mediated through RhoGDIα. Conclusions and Implications: We identified a novel aspect of PARP1 as promoter of metastasis via transcriptional regulation of RhoGDIα. Assessing RhoGDIα levels in TNBC patients might be useful to predict sensitivity to PARP inhibitors.